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AbsTrACT
Objective ParaDigMS demonstrated superior efficacy 
and comparable safety of fingolimod versus interferon 
β-1a (iFn β-1a) in paediatric- onset multiple sclerosis 
(PoMs). This study aimed to report all predefined Mri 
outcomes from this study.
Methods Patients with multiple sclerosis (Ms) (aged 
10–<18 years) were randomised to once- daily oral 
fingolimod (n=107) or once- weekly intramuscular iFn 
β-1a (n=108) in this flexible duration study. Mri was 
performed at baseline and every 6 months for up to 2 
years or end of the study (eOs) in case of early treatment 
discontinuation/completion. Key Mri endpoints included 
the annualised rate of formation of new/newly enlarging 
T2 lesions, gadolinium- enhancing (gd+) T1 lesions, new 
T1 hypointense lesions and combined unique active 
(cUa) lesions (6 months onward), changes in T2 and 
gd+ T1 lesion volumes and annualised rate of brain 
atrophy (arBa).
results Of the randomised patients, 107 each were 
treated with fingolimod and iFn β-1a for up to 2 years. 
Fingolimod reduced the annualised rate of formation 
of new/newly enlarging T2 lesions (52.6%, p<0.001), 
number of gd+ T1 lesions per scan (66.0%, p<0.001), 
annualised rate of new T1 hypointense lesions (62.8%, 
p<0.001) and cUa lesions per scan (60.7%, p<0.001) 
versus iFn β-1a at eOs. The percent increases from 
baseline in T2 (18.4% vs 32.4%, p<0.001) and gd+ 
T1 (–72.3% vs 4.9%, p=0.001) lesion volumes and 
arBa (–0.48% vs −0.80%, p=0.014) were lower with 
fingolimod versus iFn β-1a, the latter partially due to 
accelerated atrophy in the iFn β-1a group.
Conclusion Fingolimod significantly reduced Mri 
activity and arBa for up to 2 years versus iFn β-1a in 
PoMs.
InTrOduCTIOn
The overall incidence of paediatric- onset multiple 
sclerosis (PoMS) is estimated to range from 0.18 to 
0.79 per 100 000 children,1–4 except in a few regions 
where a higher incidence of >2.6 per 100 000 chil-
dren was reported.5–7 PoMS has a higher relapse 
rate, that is, a highly active inflammatory disease 
course, compared with adult- onset multiple scle-
rosis (MS).8 9
Brain MRI plays an important role in diagnosing 
and monitoring the characteristics of inflamma-
tory lesions and brain volume in MS.10 The rate 
of accrual of new T2 lesions in the first few years 
after PoMS is higher than in adults.11 PoMS is asso-
ciated with failure of age- expected brain growth 
during childhood and early adolescence, and brain 
atrophy from disease- onset to mid- adolescence and 
into adulthood.12–14 Findings suggest that T2 and 
T1 lesion volumes are comparable in patients with 
paediatric- onset and adult- onset MS when matched 
for disease duration.15 Higher T2 lesion volumes 
correlate with reduced thalamic volumes in paedi-
atric patients, and total thalamic volumes are 
reduced relative to age- expected values, even after 
correcting for reductions in head size.12 Despite 
having more frequent brain lesions in PoMS,12 16 
disability progression is slower than in adult- onset 
MS,17potentially due to a heightened compensa-
tory capacity of children during the initial phase of 
the disease.15 Retrospective cohort data, however, 
suggest that patients with PoMS reach moderate- 
to- severe disability at an earlier age compared with 
adult- onset MS.17 18
The mainstay of treatment for paediatric patients 
with relapsing MS includes agents approved for 
use in adults with MS such as interferon (IFN) β 
and glatiramer acetate.18 19 More than 40% of 
patients ultimately are switched to a high- efficacy 
disease- modifying therapy (DMT) due to subop-
timal response.20 Data on the treatment of PoMS 
are mainly supported by observational open- label 
studies. The results of the first global randomised 
phase 3 clinical trial in patients with paediatric 
MS—PARADIGMS—have been published.21 This 
study showed superior reduction with fingolimod 
treatment in annualised relapse rate (82% relative 
reduction, p<0.001) and annualised rate of forma-
tion of new or enlarging T2 lesions (52.6% relative 
reduction, p<0.001) compared with IFN β-1a at up 
to 24 months.21 The US Food and Drug Administra-
tion and European Union approved fingolimod for 
the treatment of paediatric patients (10 years of age 
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and above) with relapsing MS in the USA22 and in Europe.23 The 
present study reports the effect of fingolimod versus IFN β-1a on 
all predefined MRI outcomes and post hoc analyses of MRI data 
from the PARADIGMS study.
MeThOds
study design and patient population
PARADIGMS was a double- blind, active- controlled, parallel- 
group, multicentre study. The study was conceptualised as a flex-
ible duration design24 comprising a core phase of up to 2 years, 
followed by a 5- year fingolimod open- label extension phase, in 
paediatric patients with MS aged 10–<18 years at enrolment. 
Patients were randomised (1:1) to receive either oral fingolimod 
(dose adjusted for body weight, 0.5 mg once daily for >40 kg 
and 0.25 mg once daily for ≤40 kg) or intramuscular IFN β-1a 
30 µg once weekly in a double- dummy design.
The study included patients who had been previously treated 
or were treatment- naïve who experienced at least one relapse 
in the past year or two relapses in the previous 2 years, or who 
had evidence of one or more gadolinium- enhancing (Gd+) 
lesion on T1- weighted MRI within 6 months prior to randomi-
sation (including screening MRI) with an Expanded Disability 
Status Scale score of 0–5.5. Patient assessments during screening 
and baseline included a central review process of the diagnosis 
of paediatric MS by independent experts, on the basis of the 
patient’s clinical history and MRI scans. Further details of the 
study design and population are reported elsewhere (PARA-
DIGMS  ClinicalTrials. gov number, NCT01892722).21
MrI assessments and outcomes
MRI was assessed for all patients at screening and at months 
6, 12, 18 and 24 or at the end of the study (EOS) in case of 
early discontinuation or early completion of study treatment. 
The MRI scans were analysed independently at a central reading 
centre (NeuroRx Research, Montreal, Quebec, Canada).
The key MRI endpoint was the annualised rate of formation of 
new/newly enlarging T2 lesions up to month 24 (key secondary 
endpoint of the PARADIGMS study). Other secondary MRI 
endpoints included the proportion of patients free of Gd+ T1 
lesions at EOS, number of Gd+ T1 lesions per scan up to EOS 
and volume of Gd+ T1 lesions at EOS.
Prespecified exploratory MRI endpoints included the propor-
tion of patients free of new/newly enlarging T2 lesions up to 
month 24, change in T2 lesion volume at EOS, annualised 
rate of new T1 hypointense lesion formation up to month 24 
and change in volume of T1 hypointense lesions at EOS. The 
percent brain volume change (PBVC) from baseline to EOS and 
annualised rate of brain atrophy (ARBA) were also assessed. 
The brain volume at baseline was calculated using a modified 
version of SIENAx V.5.0.4 software, in which the segmentation 
maps of lesions were integrated into the white matter mask and 
considered part of the white matter volume. Further details are 
summarised in the online supplementary material. The PBVC 
was measured using the Paired Jacobian Integration method.25 26 
The ARBA was calculated from the PBVC, as = ((PBVC/100+1)
ˆ(365.25/#days) −1)×100, where ‘days’ stands for the scan 
date relative to day 1 for the primary analysis and relative to the 
date of the month 6 scan for the sensitivity analysis. ARBA is the 
PBVC per year, which corrects for differences in study duration 
between patients.27 Exploratory MRI endpoints also assessed the 
number of combined unique active (CUA) lesions (Gd+ lesions 
(for scans acquired with Gd) plus new/enlarging T2 lesions not 
associated with gadolinium (Gd enhancement) on scans after 6 
months up to month 24 and the proportion of patients free of 
CUA lesions at EOS.
MrI procedure
Prior to the start of the study, the neuroradiologist and MRI 
technician at each site were provided with an MRI manual, tech-
nical implementation documents, image quality requirements 
and administrative procedures. Each site performed a dummy 
run on a healthy child or an adult volunteer (unless it was speci-
fied by the site to be performed on a patient with MS) to ensure 
standardised image contrast across sites. Once the dummy run 
was accepted, all the parameter settings for the study- specific 
MRI sequences were unchanged for the duration of the study.
The primary treating physician was not allowed to view the 
MRI scans during the study in order to maintain blinding. A local 
neuroradiologist reviewed the MRI scans to see if new lesions 
were present. In cases of unexpected findings (eg, findings not 
consistent with MS) observed during the study, the primary 
treating physician was further notified by a local neuroradiol-
ogist. The central blinded MRI reading centre provided MRI 
notifications during the core phase of the study if specified MRI 
activity criteria were met for a given patient. The study physi-
cian was notified if the following criteria were met: ≥5 Gd+ 
lesions on the month 6 scan and ≥5 CUA lesions on the month 
12 scan (notification triggered at month 12), ≥5 CUA lesions 
on the month 12 scan and ≥5 new/enlarging T2 lesions on the 
month 18 scan (notification triggered at month 18), or ≥5 new/
enlarging T2 lesions on the month 18 scan and ≥5 new/enlarging 
T2 lesions on the month 24 scan (notification triggered at month 
24). Only Gd+ lesions were considered at month 6 in order 
to assess MRI activity after sufficient time had elapsed for the 
treatment to become effective. Only new/enlarging T2 lesions 
were considered from month 18 onwards, as increasing concerns 
about potential toxicity of gadolinium led to removal of the 
requirement for gadolinium administration during the conduct 
of the study.
During the study, the MRI reading centre reviewed the MRI 
scan to evaluate quality, completeness and protocol adherence. 
If a scan was incomplete or incorrectly performed, the study 
centre was requested to repeat it as soon as possible. After 
passing quality control, all scans were analysed according to the 
MRI protocol. The time point of EOS is the last MRI scan avail-
able during the blinded trial. Modifications in the MRI schedule 
were followed to avoid potential confounding effects of steroids 
for the treatment of MS relapse. In the case of relapse, no MRI 
scan was performed while a patient was on intravenous steroid 
therapy and within the 30 days following termination of steroid 
therapy. The number and volume of Gd+ lesion data obtained 
<30 days after use of a steroid for treatment of relapses was 
excluded from the Gd+ T1 analysis.
Scanning and sequences
The following five sequences were acquired: proton density- 
weighted, T2- weighted and T1- weighted scans prior to gado-
linium injection, whereas fluid attenuated inversion recovery 
(FLAIR) and T1- weighted scans after gadolinium injection. The 
FLAIR sequence was acquired after administration of gado-
linium during the 10 min wait period before acquiring the post- 
gadolinium scan. Resolution of all scans was approximately 
1×1 mm in plane and 3 mm out of plane. The use of contrast 
medium was optional from month 18; sites were allowed to 
use contrast medium if this was normally done as part of the 
site’s routine clinical practice. Magnetic field strengths included 
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Table 1 Scan geometry for MRI sequences
FOV (mm)
(GE, Siemens)
FOV
A- Pxr- L
(Philips) Matrix
FOV Phase (Siemens)
Phase FOV (GE)
rFOV (Philips) slices (n)
slice thickness 
(mm)
Phase- encoding 
direction (Siemens, 
Philips)
Frequency- 
encoding 
direction (GE)
a. Scan geometry for PDW sequences
  250 250×199 256×256 100% (Siemens, GE)
80% (Philips)
60 3 (no gap) R- L A- P
b. Scan geometry for T2W sequences
  250 250×199 256×256 100% (Siemens, GE)
80% (Philips)
60 3 (no gap) R- L A- P
c. Scan geometry for T1W sequences
  250 250×188 256×256 75% (Siemens, GE)
75% (Philips)
60 3 (no gap) R- L A- P
d. Scan geometry for FLAIR sequences
  250 250×188 256×256 75% (Siemens, GE)
75% (Philips)
60 3 (no gap) R- L A- P
A- P, anterior- posterior; FLAIR, fluid- attenuated inversion recovery; FOV, field- of- view; PDW, proton density- weighted; RFOV, reduced FOV; R- L, right- left; T1W, T1- weighted 
sequence; T2W, T2- weighted sequence.
both 1.5 Tesla (1.5T) and 3T (table 1). Further details on each 
sequence are summarised in online supplementary table S1.
statistical analysis
All the MRI outcomes were analysed on the full analysis set 
(FAS), comprising all randomised patients who received at least 
one dose of the study drug. The annualised rate of formation 
of new/enlarging T2 lesions (key secondary endpoint) was also 
analysed on the per- protocol set (all FAS patients with no major 
protocol deviations) as a supportive analysis. In addition, a 
sensitivity analysis for the annualised rate of formation of new/
enlarging T2 lesions was performed on the FAS population 
after the exclusion of patients in the IFN β-1a group who were 
neutralising antibody positive at the EOS visit. EOS was defined 
as the last assessment taken on or before the final study visit 
date. The number of new/enlarging T2 lesions was also anal-
ysed in the DMT- naïve subgroup, defined as patients who had 
not received any previous DMT prior to the study. Post hoc 
analyses of the number of new/enlarging T2 lesions for subject 
subgroups as defined by sex, age (≤12 and >12 years), body 
weight (≤40 and >40 kg) and treatment experience at baseline 
were also performed. A post hoc analysis included the propor-
tion of patients free from new T1 hypointense lesions at EOS.
All the MRI endpoints were summarised using descriptive 
statistics by treatment group and visit. The annualised rate of 
formation of new/enlarging T2 lesions, new T1 hypointense 
lesions and number of CUA lesions per scan were analysed 
using a negative binomial regression model adjusted for treat-
ment, region, pubertal status and the corresponding baseline 
value; time on study was included as an offset variable for each 
covariate (and subgroup by treatment interaction for relevant 
post hoc analyses). The least squares mean values and their 95% 
CI, estimates of the rate ratio and its 95% CI, and the p value for 
treatment comparisons are reported. The proportions of patients 
free of new MRI lesions were analysed using a logistic regres-
sion model adjusted for treatment, region, pubertal status and 
the corresponding baseline value. The volume of Gd+ lesions, 
T2 lesions and T1 hypointense lesions on MRI were analysed 
via a rank analysis of covariance (ANCOVA) model adjusted for 
treatment, region, pubertal status and relevant baseline values. 
The PBVC and ARBA up to Month 24 were analysed using an 
ANCOVA model adjusted for treatment, region, pubertal status 
and the corresponding baseline brain volume. Furthermore, a 
post hoc sensitivity analysis for PBVC re- baselined to the month 
six scan, PBVC in patients with no Gd+ lesions at baseline and 
PBVC in patients with ≥1 Gd+ lesions at baseline was conducted 
using the same approach. The least squares mean and its 95% CI, 
the estimate of between- group difference and its 95% CI, and 
the p value for treatment comparisons are reported from the 
ANCOVA model.
resuLTs
Patient disposition and baseline characteristics
Of 348 unique screenings (patients could be screened more 
than once), 215 patients were randomised into the study (fingo-
limod, n=107; IFN β-1a, n=108). Of the randomised patients, 
214 received study medication and were included in the FAS 
(fingolimod, n=107; IFN β-1a, n=107). The per- protocol set 
consisted of 197 patients. In total, 188 patients completed the 
core phase of the study (fingolimod, 100 (93.5%); IFN β-1a, 
88 (81.5%)) between July 2013 and August 2017. The sensi-
tivity analysis that excluded IFN neutralising antibody- positive 
patients included 98 patients out of 107 in the IFN β-1a treat-
ment group. Further details on patient disposition and baseline 
characteristics are reported in the primary paper.21
Overall, the mean (SD) age of the study population was 15.3 
(1.81) years, ranging between 10 and <18 years at randomisa-
tion. Most patients were Caucasian (~92%) and female (~62%); 
10 patients were in the prepubertal (Tanner staging score <2) 
at randomisation. The mean body mass index was 22.5 (4.51) 
kg/m2. Overall, MS and MRI characteristics at baseline were 
comparable between the two treatment groups. Of note, a lower 
proportion of patients in the fingolimod group were free of 
Gd+ T1 lesions at baseline compared with the IFN β-1a group 
(table 2). More patients in the fingolimod group compared 
with the IFN β-1a group completed on- study treatment at 18 
months (69% vs 51%) and 24 months (28% vs 18%). Overall, 
the median duration of exposure was 634 and 547 days for the 
fingolimod and IFN β-1a treatment groups, respectively. This 
exposure corresponded to 176.0 patient- years in the fingolimod 
group and 153.4 patient- years in the IFN β-1a group.
MrI outcomes
New/enlarging T2 lesions
The annualised rate of formation of new/enlarging T2 lesions 
up to EOS was the predefined key secondary endpoint of 
the study and was lower in patients treated with fingolimod 
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Table 2 Patient demographics and baseline characteristics (randomised; intention- to- treat cohort)
Characteristic
Fingolimod IFn β-1a Total
n=107 n=108 n=215
Age (years) 15.2±2.00 15.4±1.60 15.3±1.81
  Median (range) 16.0 (10–17) 16.0 (11–18*) 16.0 (10–18*)
Sex, female, n (%) 70 (65.4) 64 (59.3) 134 (62.3)
Race, n (%)       
  Caucasian 100 (93.5) 97 (89.8) 197 (91.6)
  American Indian or Alaska Native 3 (2.8) 2 (1.9) 5 (2.3)
  Black 1 (0.9) 4 (3.7) 5 (2.3)
  Asian 1 (0.9) 0 1 (0.5)
  Other 2 (1.9) 5 (4.6) 7 (3.3)
Weight group (kg), n (%)       
  >40 98 (91.6) 107 (99.1) 205 (95.3)
Pubertal status (Tanner staging score)†, n (%)       
  Prepubertal (<2) 7 (6.5) 3 (2.8) 10 (4.7)
  Pubertal (score ≥2) 98 (91.6) 105 (97.2) 203 (94.4)
Duration of MS since diagnosis (years) 1.1±1.25 1.4±1.48 1.2±1.38
  Median (range) 0.7 (0–8) 0.8 (0–7) 0.7 (0–8)
No. of relapses in the year before screening 1.5±0.95 1.5±0.92 1.5±0.93
  Median (range) 1.0 (0–4) 1.0 (0–7) 1.0 (0–7)
No. of relapses in the 2 years before screening 2.4±1.44 2.5±1.32 2.4±1.38
  Median (range) 2.0 (0–8) 2.0 (1–9) 2.0 (0–9)
Treatment history, n (%)       
  Treatment- naïve 69 (64.5) 67 (62.0) 136 (63.3)
  Any IFN β 34 (31.8) 35 (32.4) 69 (32.1)
  Glatiramer acetate 6 (5.6) 9 (8.3) 15 (7.0)
  Natalizumab 2 (1.9) 2 (1.9) 4 (1.9)
  Dimethyl fumarate 0 (0.0) 1 (0.9) 1 (0.5)
No. of Gd+ T1 lesions n=106 n=107 n=213
  Mean (SD) 2.6±6.01 3.1±6.49 2.9±6.25
  Median (range) 1.0 (0–52) 0.0 (0–37) 1.0 (0–52)
Proportion of patients free from Gd+ lesions, n (%) 47 (44.3) 59 (55.1) 106 (49.8)
Volume of Gd+ T1 lesions (mm3) n=106 n=107 n=213
  Mean (SD) 454 (1190.4) 412 (936.6) 433 (1068.1)
  Median (range) 73 (0–9662) 0 (0–6160) 23 (0–9662)
No. of T2 lesions n=107 n=107 n=214
  Mean (SD) 41.9 (30.33) 45.6 (33.85) 43.7 (32.11)
  Median (range) 31.0 (2–126) 32.0 (4–145) 31.5 (2–145)
Proportion of patients free from T2 lesions, n (%) 0 0 0
Volume of T2 lesions (mm3) n=107 n=107 n=214
  Mean (SD) 8902 (13 147.6) 11 512 (15 087.0) 10 207 (14 177.8)
  Median (range) 5245 (52–116 533) 6197 (189–101 099) 5548 (52–116 533)
Volume of T1 hypointense lesions (mm3) n=107 n=107 n=214
  Mean (SD) 1591 (3906.5) 2609 (5823.8) 2100 (4973.3)
  Median (range) 484 (0–35 394) 753 (0–46 893) 592 (0–46 893)
Whole brain volume (cm3) n=107 n=105 n=212
  Mean (SD) 1154 (126.8) 1160 (121.5) 1157 (124.0)
  Median (range) 1146 (917–1633) 1136 (910–1487) 1139 (910–1633)
*These individuals were confirmed as being <18 years of age at randomisation; local laws permitted only their birth year to be recorded.
†Tanner staging scores, based on the higher score assigned for breast development and for pubic hair assessment in female patients, and the higher score assigned for genital 
stage and for pubic hair assessment in male patients. A bone age ≥16 years and/or menarche for female patients was considered as pubertal if the Tanner staging score was 
missing. n, number of patients included in each analysis.
Gd+, gadolinium- enhancing; IFN, interferon; MS, multiple sclerosis.
compared with IFN β-1a (52.6% relative reduction, p<0.001; 
table 3).21 The robustness of this result was further confirmed 
by supportive analyses in the per- protocol set, which demon-
strated a similar risk reduction (month 0 to EOS: 51.6% rela-
tive reduction, p<0.001).28 In addition, further supporting the 
robustness of the results, a sensitivity analysis excluding patients 
positive for interferon neutralising antibodies in the IFN β-1a 
treatment group showed a slightly lower risk reduction in this 
result at EOS (47.6%, p<0.00128; figure 1). The proportion of 
patients free of new/enlarging T2 lesions at EOS was higher in 
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Table 3 Effect of fingolimod on MRI inflammatory lesion activity at EOS (FAS)
MrI outcomes
Adjusted mean number (95% CI) between- treatment comparison
Fingolimod
n=107
IFn β-1a
n=107
rate ratio
(95% CI) rate reduction (%) P value
Annualised rate of new/enlargingT2 lesions (per patient per year)* n=106
4.39
(3.617 to 5.336)
n=102
9.27
(7.661 to 11.214)
0.47
(0.361 to 0.622)
52.6 <0.001
No. of Gd+ T1 lesions per scan† n=106
0.44
(0.313 to 0.608)
n=101
1.28
(0.934 to 1.758)
0.34
(0.215 to 0.540)
66.0 <0.001
Annualised rate of new T1 hypointense lesions (per patient per year)‡ n=107
4.50
(3.468 to 5.828)
n=96
12.10
(9.242 to 15.830)
0.37
(0.255 to 0.542)
62.8 <0.001
No. of CUA lesions per scan§¶ n=104
2.40
(1.850 to 3.100)
n=98
6.09
(4.702 to 7.881)
0.39
(0.273 to 0.567)
60.7 <0.001
EOS is defined as the last assessment taken on or before the final study phase visit date. n, number of patients included in each analysis.
*Obtained from fitting a negative binomial regression model adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline T2 lesion number (offset: time on study).
†Obtained from fitting a negative binomial regression model with the cumulative number of Gd+ T1 lesions on all scheduled post- baseline MRI scans during the study as the response variable, 
adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline number of Gd+ T1 lesions (offset: number of MRI scans).
‡Obtained from fitting a negative binomial regression model with cumulative number of new T1 hypointense lesions adjusted for treatment, region and pubertal status (the stratification factor in 
IVRS) (offset: time on study).
§Obtained from fitting a negative binomial regression model adjusted for treatment, region, pubertal status (the stratification factor in IVRS), baseline number of Gd+ T1 lesions and baseline 
number of T2 lesions.
¶CUA lesion count is defined as Gd+ lesions plus new/newly enlarging T2 lesions not associated with Gd enhancement for scans performed after Gd administration, or only new/newly enlarging 
T2 lesions for scans done without contrast. CUA lesions were measured from 6 months onwards.
CUA, combined unique active; EOS, end of the study; FAS, full analysis set; Gd+, gadolinium- enhancing; IFN, interferon; IVRS, interactive voice response system.
Figure 1 annualised rate of the number of new/enlarging T2 lesions 
from baseline by time point (sensitivity analysis)ˆ. *p≤0.05 vs iFn β-1a; 
**p≤0.001 vs iFn β-1a. Data are expressed as adjusted mean±95% ci. 
n, number of patients included in each analysis. eOs is defined as the last 
assessment taken on or before the final study phase visit date. ˆanalysis 
excluding patients positive for neutralising antibodies in the iFn β-1a 
treatment group–nine iFn patients were positive for antibodies. aObtained 
from fitting a negative binomial regression model adjusted for treatment, 
region, pubertal status (the stratification factor in iVrs) and baseline 
number of T2 lesions (offset: time on study). eOs, end of the study; iFn, 
interferon; iVrs, interactive voice response system.
Figure 2 Proportion of patients free of Mri endpoints (Fas). *p≤0.05 vs 
iFn β-1a; **p≤0.001 vs iFn β-1a. nʹ, number of patients free from Mri 
outcomes; n, number of patients included in each analysis. cUa lesion 
count is defined as gd+ lesions plus new/newly enlarging T2 lesions 
not associated with gd enhancement for scans performed after gd 
administration, or only new/newly enlarging T2 lesions for scans done 
without contrast. cUa lesions were measured from 12 months onwards. 
eOs is defined as the last assessment taken on or before the final study 
phase visit date. Proportions of patients free from new Mri lesions 
were analysed using a logistic regression model adjusted for treatment, 
region, pubertal status and the corresponding baseline value. cUa, 
combined unique active; eOs, end of the study; Fas, full analysis set; gd+, 
gadolinium- enhancing; iFn, interferon.
fingolimod- treated patients compared with those treated with 
IFN β-1a (16.0% vs 3.9%, p=0.011; figure 2). The mean per 
cent increase in T2 lesion volume from baseline at EOS was 
lower with fingolimod treatment compared with IFN β-1a 
(18.4% vs 32.4%, p<0.001; table 4).
Gd+ T1 lesions
Treatment with fingolimod resulted in a 66.0% reduction in the 
number of Gd+ T1 lesions per scan compared with IFN β-1a 
at EOS (p<0.001; table 3).21 A higher proportion of patients in 
the fingolimod group were free of Gd+ T1 lesions compared 
with the IFN β-1a group at EOS (77.4% vs 53.5%, p<0.001; 
figure 2). The mean percent change in Gd+ T1 lesion volume 
from baseline showed a decrease in fingolimod- treated patients 
compared with a slight increase in those treated with IFN β-1a 
over the study period (–72.3% vs 4.9%, p=0.001; table 4).
T1 hypointense lesions
The annualised rate of formation of new T1 hypointense lesions 
was reduced with fingolimod treatment compared with the IFN 
β-1a group at EOS (62.8% rate reduction, p<0.001; table 3). 
This reduction in new T1 lesion formation was consistently 
observed in fingolimod- treated patients compared with IFN 
β-1a throughout the study. The percent change from baseline 
in T1 hypointense lesion volume between the fingolimod and 
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Table 4 Effect of fingolimod on MRI volumes at EOS (FAS)
MrI outcomes
Mean baseline volumes Mean percent change from baseline between- treatment comparison
Fingolimod
n=107
IFn β-1a
n=107
Fingolimod
n=107
IFn β-1a
n=107
Mean difference
(95% CI) P value
T2 lesion volume* (mm3) n=107
8902
n=106
11 455
n=107
18.4%
n=102
32.4%
– <0.001
Gd+ T1 lesion volume† (mm3) n=106
455
n=106
416
n=59
–72.3%
n=45
4.9%
– 0.001
T1 hypointense lesion volume‡ (mm3) n=107
1591
n=106
2600
n=105
98.9%
n=99
81.9%
– 0.502
Annual rate of brain atrophy§ (cm3) (95% CI) n=107
1154
n=104
1161
n=96
–0.48%
(–0.65 to –0.30)
n=89
–0.80%
(–0.98 to –0.61)
0.32
(0.06 to 0.57)
0.014
(–) indicates a decrease in values versus baseline. n, number of patients included in each analysis. EOS is defined as the last assessment taken on or before the final study phase 
visit date.
*Obtained from fitting a rank ANCOVA model adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline total volume of T2 lesions.
†Obtained from fitting a rank ANCOVA model adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline total volume of Gd+ T1 lesions.
‡Obtained from fitting a rank ANCOVA model adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline T1 hypointense lesion volume.
§Obtained from fitting an ANCOVA model adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline whole brain volume.
ANCOVA, analysis of covariance;EOS, end of the study; FAS, full analysis set; Gd+, gadolinium- enhancing; IFN, interferon; IVRS, interactive voice response system.
Figure 3 Mean number of cUa lesions per scan by time point (Fas). 
*p≤0.05 vs iFn β-1a; **p≤0.001 vs iFn β-1a. Data are expressed as 
adjusted mean±95% ci. n, total number of patients with an available 
result for the corresponding time point or time window and included 
in the analysis. cUa lesion count is defined as gd+ lesions plus new or 
newly enlarging T2 lesions not associated with gd enhancement for scans 
performed after gd administration, or only new or newly enlarging T2 
lesions for scans done without contrast. cUa lesions were measured from 
6 months onwards. eOs is defined as the last assessment taken on or 
before the final study phase visit date. aObtained from fitting a negative 
binomial regression model adjusted for treatment, region, pubertal status 
(the stratification factor in iVrs), baseline number of gd+ T1 lesions and 
baseline number of T2 lesions (offset: number of Mri scans). cUa counts 
based on data obtained <30 days after steroid treatment was used to treat 
Ms relapses are excluded. cUa, combined unique active; eOs, end of the 
study; Fas, full analysis set; gd+, gadolinium- enhancing; iFn, interferon; 
iVrs, interactive voice response system; Ms, multiple sclerosis.
IFN β-1a treatment groups was not significant at EOS (table 4) 
and consistently did not reach statistical significance throughout 
the study. The post hoc analysis results showed that the propor-
tion of patients free of new T1 hypointense lesions was higher 
with fingolimod treatment than with IFN β-1a at EOS (22.4% 
vs 11.5%, p<0.048).
CUA lesions
The CUA lesions were reported at month 12 onwards. There 
was a significant reduction in the number of CUA lesions per 
scan at months 12, 18, 24 and EOS with fingolimod treatment 
compared with IFN β-1a (figure 3). A relative reduction rate of 
60.7% (p<0.001) was observed at EOS (table 3). Treatment with 
fingolimod resulted in more patients free of CUA lesions at EOS 
(51.0% vs 19.4%; p<0.001; figure 2).
Percent brain volume change
Fingolimod treatment resulted in reduction of ARBA versus IFN 
β-1a (−0.48% vs −0.80%), with a between- treatment differ-
ence of 0.32 (p=0.014; table 4) at EOS.21 Significantly lower 
brain volume loss was observed in fingolimod- treated patients 
at months 6, 12, 18 and 24 and EOS than in IFN β-1a–treated 
patients (figure 4). The sensitivity analysis (post hoc) re- baselined 
to the month 6 scan showed a numerical but not statistically 
significant lower BVL for fingolimod- treated patients (figure 5). 
A box and whisker plot of the ARBA (re- baselined 6 months) at 
EOS is provided in the online supplementary figure S1. Similar 
trends in favour of fingolimod compared with IFN β-1a were 
observed in patients who had no Gd+ lesions at baseline (online 
supplementary figure S2) and those who had ≥1 Gd+ lesions at 
baseline (online supplementary figure S3).
Post hoc analyses of new/enlargingT2 lesions
Compared with baseline, the annualised rate of new/enlarging T2 
lesions for each subgroup—sex, age, body weight, and treatment 
experience at baseline—was consistently lower in the fingolimod 
group than in the IFN β-1a group at EOS (table 5). There was a 
reduction in the annualised rate of formation of new/enlarging 
T2 lesions at EOS with fingolimod compared with IFN β-1a in 
both male (54.2%, p<0.001) and female (53.2%, p<0.001) 
and in subgroups of patients aged >12 years (53.7%, p<0.001) 
and weighing >40 kg (53.0%, p<0.001), as well as prior DMT- 
experienced patients (51.4%, p=0.002) and in the DMT- naïve 
subgroup (53.4%, p<0.001).28
dIsCussIOn
In this first randomised phase 3 study in paediatric patients with 
MS (aged 10–<18 years), fingolimod significantly reduced brain 
MRI activity and slowed the annualised rate of brain volume 
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Figure 4 Percent change from baseline in brain volume by time point 
(Fas). *p≤0.05 vs iFn β-1a; **p≤0.001 vs iFn β-1a. Data are expressed as 
adjusted mean±95% ci. n, number of patients included in each analysis. 
eOs is defined as the last assessment taken on or before the final study 
phase visit date. aObtained from fitting an ancOVa model adjusted for 
treatment, region, pubertal status (the stratification factor in iVrs) and 
baseline normalised brain volume. ancOVa, analysis of covariance; eOs, 
end of the study; Fas, full analysis set; iFn, interferon; iVrs, interactive 
voice response system.
Figure 5 Percent change in brain volume (re- baselined from 6 months) 
by time point (Fas). Data are expressed as adjusted mean±95% ci. n, 
number of patients included in each analysis. eOs is defined as the last 
assessment taken on or before the final study phase visit date. aObtained 
from fitting an ancOVa model adjusted for treatment, region, pubertal 
status (the stratification factor in iVrs) and 6- month baseline normalised 
brain volume as covariates. ancOVa, analysis of covariance; eOs, end 
of the study; Fas, full analysis set; iFn, interferon; iVrs, interactive voice 
response system.
loss compared with IFN β-1a for up to 2 years. Compared 
with IFN β-1a, treatment with fingolimod resulted in relative 
risk reductions of 52.6% for new/enlarging T2 lesions, 66% for 
Gd+ lesions and 60.7% for CUA lesions, as well as reduction 
of ARBA (between- treatment difference: 0.32). Approximately 
77% of patients in the fingolimod group and 54% in the IFN 
β-1a group were free of Gd+ lesions at EOS. Furthermore, 51% 
of patients on fingolimod and 19.4% of patients on IFN β-1a 
were free of Gd+ lesions or new/enlarging T2 lesions not associ-
ated with Gd enhancement (ie, accrued CUA lesions). Subgroup 
analysis results found that the relative reduction in annualised 
rate of formation of new/enlargingT2 lesions was similar in 
both male and female, and in patients who were DMT- naïve or 
DMT- experienced at baseline, consistent with the findings in 
the overall study population, confirming the efficacy of fingo-
limod treatment in children regardless of sex or prior treatment 
experience. When analysed by age and body weight, patients 
treated with fingolimod had consistently lower lesion counts. 
This was significant only for patients aged >12 years or with 
body weight >40 kg at baseline, likely related to the low sample 
size in patients ≤12 years of age and with a body weight <40 kg.
MRI disease activity in the paediatric population was gener-
ally higher at baseline (mean age: 15.3 years; T2 lesion volume 
10 207 mm3; Gd+ T1 lesions 2.9) than the disease activity 
observed in a comparable adult population recruited for an 
actively controlled clinical trial (mean age: 36 years; T2 lesion 
volume 4924 mm3; Gd+ T1 lesions 1.06).29 The high baseline 
disease activity observed in the present study is consistent with 
previous observations of higher activity in young adult patients30 
compared with adult- onset MS. For example, the disease activity 
as measured by the annualised rate of formation of new/enlarging 
T2 lesions and number of Gd+ T1 lesions per scan after at least 
3 months were 4.39 and 0.44, respectively, with fingolimod 
treatment and 9.27 and 1.28, respectively, with IFN β-1a in 
the present study. The T2 lesion rate in our study was 2.6- fold 
greater with fingolimod and 3.5- folder greater with IFN β-1a 
than observed in adult patients with MS in the 12- month TRANS-
FORMS study (fingolimod: 1.7 and IFN β-1a: 2.6).29 Similarly, 
Gd+ T1 lesion rate was 2.0- fold greater with fingolimod and 
2.5- fold greater with IFN β-1a than observed in the TRANS-
FORMS study (fingolimod: 0.23 and IFN β-1a: 0.51).29 This 
finding of higher inflammatory activity in the paediatric popu-
lation compared with adults is further substantiated by looking 
at the proportion of patients free of T2 lesions. The proportions 
of patients free of T2 lesions were approximately 3.4- fold lower 
on fingolimod (16%) and 12- fold lower on IFN β-1a (3.9%) in 
the present paediatric study compared with the adult TRANS-
FORMS study (fingolimod: 54.8%; IFN β-1a: 45.7%).29 Thus, 
our findings from the first randomised controlled clinical trial in 
paediatric patients with MS confirms that inflammatory disease 
activity in children with MS is substantially higher than in adult 
patients with MS.
Due to the high frequency of new lesion formation in the 
paediatric patients in the present study and the time it takes 
for DMTs to achieve full efficacy, only 24% of patients were 
free of new/newly enlarging T2 lesions on the month six scan. 
An analysis of activity re- baselined to the scan at 6 months was 
conducted using CUA lesions, which were assessed from 12 
months onwards (with reference to the previous scan). Approx-
imately 51% of the patients on fingolimod and 19.4% of the 
patients on IFN β-1a were free of CUA lesions from month 6 
to EOS.
Achievement of no evidence of disease activity may be an 
outcome of interest for future studies, but the present study 
suggests that no evidence of disease activity in paediatric patients 
with MS may not be observed even with agents that demonstrate 
a powerful effect on clinical disease.
In contrast to placebo- controlled studies, the present study 
showed a greater suppression of relapses (82%)21 than MRI 
activity (52.6% for new/newly enlarging T2 lesions; 66.0% for 
Gd+ lesions). This can be attributed to the use of the active 
comparator, IFN β-1a, which itself suppresses MRI activity more 
than relapses (28%–57% vs 18%, respectively).31–34
Children with MS have a smaller head size, brain volume and 
thalamic volume compared with age- matched and sex- matched 
healthy children, and failure of age- anticipated brain growth.11-13 
Our study observed a relative reduction of 40% in brain volume 
loss with fingolimod compared with IFN β-1a which itself slows 
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Table 5 Annualised rate of new/enlargingT2 lesions at EOS by subgroups (FAS)
subgroups
Adjusted mean number (95% CI) between- treatment comparison
Fingolimod
n=107
IFn β-1a
n=107
rate ratio
(95% CI) rate reduction (%) P value
Sex
  Male n=36
3.47
(2.471 to 4.880)
n=42
7.59
(5.647 to 10.199)
0.46*
(0.292 to 0.718)
54.2 <0.001
  Female n=70
4.88
(3.850 to 6.193)
n=60
10.44
(8.175 to 13.339)
0.47*
(0.332 to 0.658)
53.2 <0.001
Age
  ≤12 years n=13
4.3
(2.188 to 8.437)
n=8
6.28
(3.049 to 12.949)
0.68*
(0.264 to 1.772)
31.6 0.434
  >12 years n=93
4.41
(3.568 to 5.448)
n=94
9.51
(7.806 to 11.596)
0.46*
(0.348 to 0.618)
53.7 <0.001
Body weight
  ≤40 kg n=9
4.74
(2.150 to 10.456)
n=1
7.05
(0.992 to 50.136)
0.67*
(0.080 to 5.624)
32.8 0.714
  >40 kg n=97
4.36
(3.552 to 5.359)
n=101
9.29
(7.671 to 11.251)
0.47*
(0.355 to 0.622)
53.0 <0.001
DMT- experienced n=38
5.19
(3.751 to 7.177)
n=38
10.68
(7.810 to 14.601)
0.49†
(0.308 to 0.766)
51.4 0.002
DMT- naïve n=68
3.90
(3.062 to 4.974)
n=64
8.38
(6.589 to 10.645)
0.47†
(0.330 to 0.658)
53.4 <0.001
EOS is defined as the last assessment taken on or before the final study phase visit date. n, number of patients included in each analysis.
*Obtained from fitting a negative binomial regression model adjusted for treatment, region, pubertal status (the stratification factor in IVRS), subgroup, subgroup- by- treatment 
interaction and baseline number of T2 lesions (offset: time in study).
†Obtained from fitting a negative binomial regression model adjusted for treatment, region, pubertal status (the stratification factor in IVRS) and baseline number of T2 lesions 
(offset: time in study).
DMT, disease- modifying therapy; EOS, end of the study; FAS, full analysis set; IFN, interferon; IVRS, interactive voice response system.
brain volume loss over 2 years.35 A large part of this differ-
ence appeared in the first 6 months following treatment initia-
tion, and may have reflected the accelerated atrophy known to 
occur after initiation of treatment with IFN β-1a.36 Subsequent 
differences between groups in brain volume were smaller, and 
only numerically (ie, not significantly) in favour of fingolimod, 
reflecting a slowing of atrophy with fingolimod that is greater 
than that expected to occur with IFN β-1a.37 Despite treatment, 
these young patients showed brain volume loss rather than age- 
anticipated increases, emphasising the negative impact of MS in 
the maturing central nervous system. The resilience of children 
to the development of early physical disability should not be a 
cause for complacency with respect to the need for highly effec-
tive therapies. Furthermore, considerations relating to whether 
a given therapy is capable of mitigating the progressive brain 
atrophy seen in PoMS require more information relating to the 
natural history of brain volume loss and the potential that MS 
has a particularly detrimental impact on brain maturation unique 
to the paediatric MS population.
The behaviour of T1 hypointense lesion volume deserves 
special consideration. The percentage increase in T1 hypointense 
lesion volume was substantially greater than the percentage 
increase in T2- weighted lesion volume, and the number of 
new T1 hypointense lesions may have been greater than the 
number of new/enlarging T2- weighted lesions. These observa-
tions may be explained by the recent findings related to ongoing 
degeneration within existing T2- weighted lesions,38 and may 
indicate that degenerative processes associated with progressive 
disease are already present in PoMS. This finding also suggests 
that even very young patients with MS fail to fully remyelinate 
within lesions, further emphasising the need for therapies that 
reduce new T2 lesion formation.
We conclude that treatment with fingolimod showed better 
efficacy compared with IFN β-1a in reducing MRI activity, 
relapses and brain volume loss, supporting the overall beneficial 
effect of fingolimod in paediatric patients with MS. Fingolimod 
provides an effective treatment option for children and adoles-
cents with MS.
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